- About Us
-
Our Business
-
- Therapeutic Areas Our portfolio is diverse and based upon - Market Research, Regulatory & IP.
- Licensing Licensing activities are excellent opportunities for companies to expand their portfolio.
- Biosimilar Biosimilar are biologic medicines that are developed to match their reference medicine.
-
- CRAM India has grown to be one of the key nations complying GMP manufacturing norms.
- Medical Devices REVA help our clients to deliver customized, cost-effective medical device value chain.
-
API
-
Dosage form
-
-
Operations
- At Reva, we have requisite infrastructure, with a balanced reach across Regulated, Emerging & Expansion markets. And we are committed to helping create healthier communities worldwide through education, outreach and better access to treatment.
-
Research & Development
-
Manufacturing
-
Quality
- Media
- Contact us
Latest News
About 70 per cent of India’s total activated pharmaceutical ingredients requirement is met by imports from...
Read More
Read More
.jpg)
The Centre has restricted the export of 26 active pharmaceutical ingredients and drug formulations used as raw materials...
Read More
Read More
Pharmaceutical companies that market drugs will now fall under the ambit of the Drugs and Cosmetics Act (DCA), according...
Read More
Read More
The Council for Healthcare and Pharma today cited the urgent need to strengthen the system for the treatment of cancers...
Read More
Read More
For one coronavirus patient at ground zero of the outbreak, the journey from infection to recovery was a nightmare...
Read More
Read More
The dependence of pharmaceutical companies on China when it comes to active pharmaceutical ingredients (APIs),...
Read More
Read More
Development of Vaccine Against New Coronavirus Progressing Well: U.S. Health Official WASHINGTON, A U.S. health...
Read More
Read More
Now that a case of infection by the novel coronavirus (2019-nCoV) has been flagged in India, central and state...
Read More
Read More
Drug major Cipla has acquired the nutrition products portfolio from Mumbai-based Wanbury for an undisclosed sum. ...
Read More
Read More
The next Union budget is just around the corner. The Council for healthcare and Pharma (CHP) lauds the efforts of the...
Read More
Read More
Over the last several years, many a vision statement projected a robust trajectory for the pharmaceutical industry by...
Read More
Read More
The Rs 14,000-crore diabetes drug market in the country is witnessing a churn with many patents reaching their expiry....
Read More
Read More